PMVP
PMV Pharmaceuticals, Inc. [PMVP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PMVP Stock Summary
Top PMVP Correlated Resources
PMVP
Top 10 Correlated ETFs
PMVP
Top 10 Correlated Stocks
PMVP
In the News
PMVP Financial details
Company Rating
-
Market Cap
92.08M
Income
-66.61M
Revenue
1.62M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.82
Forward P/E
-
PEG
1.4
P/S
-
P/B
0.54
P/C
-
P/FCF
-2.17
Quick Ratio
18.84
Current Ratio
19.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.4
EPS next Y
-
EPS next Q
-
EPS this Y
-10.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-8.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-30%
ROC
-0.33%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.175-9.72
52W High
-88.78%
52W Low
+1%
RSI
23
Rel Volume
0.25
Avg Volume
565.82K
Volume
141.93K
Perf Week
-12.93%
Perf Month
-28.37%
Perf Quarter
-33.11%
Perf Half Y
-32.67%
-
-
-
-
Beta
1.64
-
-
Volatility
0.04%, 0.11%
Prev Close
-7.34%
Price
1.01
Change
-11.4%
Company Profile
- Volume Average 565.82K
- Market Capitalization 92.08M
- Employee 63
- CEO Dr. David H. Mack Ph.D.
- Headquarters Cranbury,NJ,US
- IPO Date 2020-09-25
-
Website
https://www.pmvpharma.com 
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
